Author:
Rochau U.,Jahn B.,Qerimi V.,Burger E.A.,Kurzthaler C.,Kluibenschaedl M.,Willenbacher E.,Gastl G.,Willenbacher W.,Siebert U.
Reference56 articles.
1. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant;Blade;Br J Haematol,1998
2. Continued improvement in survival in multiple myeloma and the impact of novel agents,2012
3. When should decision-analytic modeling be used in the economic evaluation of health care? [Editorial];Siebert;Eur J Health Econ,2003
4. Phillips C. What is cost–effectiveness? Health economics 2009. What is...? series. 2nd ed., p. 1–8 [Epub]
5. University of York, Centre for Reviews and Dissemination. Available from: http://www.crd.york.ac.uk/CRDWeb/ [last accessed 02.13.14]; 2013.
Cited by
11 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献